José Luís
Zamorano Gómez
Catedrático/a de Universidad
Pierre and Marie Curie University
París, FranciaPublicacións en colaboración con investigadores/as de Pierre and Marie Curie University (6)
2022
-
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid
Pharmacology and Therapeutics, Vol. 237
2020
-
2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
European Heart Journal, Vol. 41, Núm. 1, pp. 111-188
2019
-
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine
American Journal of Cardiovascular Drugs, Vol. 19, Núm. 2, pp. 173-183
2018
-
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
European Heart Journal, Vol. 39, Núm. 14, pp. 1131-1143
-
New prospects for PCSK9 inhibition?
European heart journal
2016
-
Effect of Pre-Hospital Ticagrelor during the First 24 h after Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction the ATLANTIC-H24 Analysis
JACC: Cardiovascular Interventions, Vol. 9, Núm. 7, pp. 646-656